Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an increased risk of thromboembolic complications and stroke. Therefore, the implementation of thromboembolic preventive treatment is the cornerstone of quality management in AF patients. During the last 60 years, vitamin K antagonists remain at the forefront of antithrombotic management of AF patients. Randomized trials have demonstrated their superiority over aspirin as well as over the combination of aspirin and clopidogrel with similar safety profile. However, the disseminated use of vitamin K antagonists among suitable candidates is hampered by their inherent limitations. As a result, a considerable proportion of AF patients do not receive this life-saving therapy. In the last few years, novel anticoagulants targeting factors IIa (dabigatran) and Xa (rivaroxaban, apixaban, edoxaban) in the coagulation cascade have been developed. Recently completed phase III mega-trials of dabigatran, rivaroxaban and apixaban have provided cumulative evidence in favor of these novel anticoagulants. Their main advantages, apart from their treatment efficacy, include the reduced rate of intracranial hemorrhage, the lack of need for routine coagulation monitoring, the predictable anticoagulation response and the limited interaction with food and drugs. In the present manuscript we present a critical appraisal of the recent trials focusing on issues that are expected to influence decision making on selection of novel anticoagulants.
Atrial fibrillation (AF) is the most common cardiac arrhythmia with increasing prevalence and incidence with age and a considerable impact on morbidity and mortality. 1, 2 The major complication of AF is the occurrence of stroke. Atrial fibrillation is associated with a 5-fold increased stroke risk overall and a 2-fold higher risk of stroke after adjustment for other risk factors. 3 The annual rate of stroke among patients with AF without implementation of any type of preventive treatment is 5% and exceeds 7% when transient ischemic attacks (TIAs) and silent strokes are taken into account. 4 Furthermore, AFrelated strokes are more severe and are associated with poorer patient outcome, increased morbidity, and mortality in comparison with non-AF-related strokes. 5, 6 It is also worth noting that based on the results of the on-treatment analysis of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study, the occurrence of stroke or TIA is an independent predictor of mortality among patients with AF and the use of anticoagulants markedly reduces the risk of death. 7 Therefore, antithrombotic management is a mainstay in the treatment of patients with AF.
Vitamin K Antagonists
During the last 60 years, vitamin K antagonists (VKAs) have been the main treatment option for the prevention of thromboembolic events among patients with AF. Adjusteddose warfarin has been shown to reduce the risk of stroke by 64% (absolute risk reduction of 2.7%) in comparison with placebo or no treatment in patients with AF. 8 Despite the fact that the use of warfarin is independently associated with improved survival among patients with AF, 7 the actual prescription rate of VKA is limited to 48% to 65% of suitable anticoagulation candidates. [9] [10] [11] The considerable underutilization of this lifesaving therapy reflects the well-acknowledged limitations of VKA treatment, such as narrow therapeutic range, drug-drug and food-drug interactions, unpredictable response, slow onset of action, and need for routine coagulation monitoring. 12 Thus, patients may avoid VKAs and physicians are reluctant to prescribe anticoagulants, mostly to elderly patients with AF, due to the concerns about suboptimal treatment monitoring and increased risk of hemorrhagic complications.
The efficacy and safety of anticoagulation vary in relation to the quality of control of the international normalized ratio (INR). Prolonged time in the target INR range of 2.0 to 3.0 (time to therapeutic range [TTR]) is associated with reduced risk of ischemic stroke, major hemorrhage, and with lower mortality. 13, 14 In a recent meta-analysis, patients with AF were within the therapeutic INR range only 55% of the time, with even poorer control among those treated in a community care setting. 11 The low TTR values achieved in the real world explain at least partly the discrepancy in ischemic stroke reduction between patients with AF treated with anticoagulants in clinical trials compared with everyday practice (64% relative risk reduction in a meta-analysis of randomized trials vs 35% in Medicare beneficiaries). 9 Furthermore, the efficacy superiority of VKA over clopidogrel plus aspirin is abrogated among patients with TTR values less than 58% to 65%, due to diminished treatment benefit gained by VKA therapy. 15 
Role of Antiplatelet Agents
Antiplatelet agents have been tested as a means for thromboprohylaxis among patients with AF in search of an alternative to VKA with equivalent efficacy but devoid of the relevant limitations. Aspirin is associated with a 22% stroke reduction in comparison with placebo or no treatment. 8 Dual antiplatelet treatment with clopidogrel plus aspirin further reduces the occurrence of stroke compared with aspirin monotherapy but with an increased rate of major bleeding. 16 However, adjusted-dose warfarin has been shown to be superior not only to aspirin monotherapy (38% relative reduction in stroke risk) 8 but also to combined aspirin plus clopidogrel treatment. 17 It is noteworthy that the superiority of warfarin over dual antiplatelet treatment was accompanied with similar rate in hemorrhagic complications. 17 Antiplatelet treatment has been considered an attractive alternative over warfarin in elderly patients with AF on the assumption of safety over efficacy in a patient group which is more prone to hemorrhagic complications and less likely to adhere to instructions regarding VKA therapy. 18 However, several data seem to challenge this notion. In contradiction to oral anticoagulants, the relative benefit of antiplatelet agents for preventing ischemic stroke in patients with AF significantly decreases with age. 19 antiplatelet agents seem to be ineffective among AF patients older than 77 years. 19 Furthermore, the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) trial clearly demonstrated the superior efficacy of warfarin over low-dose aspirin for stroke prevention in AF patients older than 75 years with an unexpected similarity in the risk of major hemorrhages in both groups. 20 Therefore, increased age per se should not be considered an argument to favor antiplatelet agents over VKA therapy for thromboprophylaxis among patients with AF. On the other hand, a rather undervalued treatment option is the combination of antiplatelet and moderate intensity anticoagulation therapy. In the NAtional Study for Prevention of Embolism in Atrial Fibrillation (NASPE-AF) trial, the combination of the cyclooxygenase inhibitor triflusal plus VKA (target INR 1.25-2.0) significantly reduced the occurrence of vascular events compared with standard anticoagulation therapy (INR 2.0-3.0) with a similar safety profile ( Figure 1 ). 21 
Novel Anticoagulants
The abovementioned limitations of the available pharmacologic options for prevention of stroke in patients with AF have prompted research for novel anticoagulants. Two main classes of anticoagulant agents have been introduced, targeting key factors for the coagulation cascade: thrombin (factor IIa) and the activated factor Xa. The oral direct thrombin inhibitor, dabigatran etexilate, is a representative of the first class. The second group of Xa inhibitors, includes several agents at different stages of clinical development, with rivaroxaban and apixaban having already completed phase III mega trials with results that hold promise for use in everyday clinical practice (Table 1) .
Dabigatran Etexilate
Dabigatran etexilate is a new oral direct thrombin inhibitor, with a predictable anticoagulant effect that obviates the need for regular coagulation monitoring and lack of clinically meaningful drug and food interactions. The drug has a half-life of 12 to 17 hours with a twice-daily (bid) dosing regimen. After an extensive clinical program for prevention of thromboembolism in orthopedic patients, the Randomized Evaluation of Long-term anticoagulation therapY (RELY) trial, a large, open-label, phase III trial compared 2 different doses of dabigatran given bid (110 and 150 mg) vs warfarin (target INR 2.0-3.0) in patients with AF with a primary efficacy end point of stroke or systemic embolism and a primary safety end point of major bleeding. 22 The 150-mg dabigatran dose was shown to significantly reduce stroke and systemic embolism with similar rates of major bleeding compared with warfarin (superior efficacy with similar safety). On the other hand, the 110-mg dabigatran dose resulted in similar rates of stroke and systemic embolism in comparison to warfarin but with lower rates of major bleeding (similar efficacy with superior safety). Based on these results, the clinician has the option to tailor the dabigatran dosing to the bleeding risk of each patient. It should also be highlighted that both doses of dabigatran reduced by about two thirds the risk of intracranial bleeding, which was not the case when ximelagatran (another direct thrombin inhibitor which has been withdrawn due to reported hepatotoxicity) was compared with warfarin. 23 The significantly lower rate of intracranial bleeding was consistent in both doses of dabigatran irrespective of the quality of INR control and the level of TTR achieved. 24 In the recent guidelines issued by the European Society of Cardiology (ESC), dabigatran has been proposed as an alternative to adjusted-dose VKA therapy in patients with AF in need of thromboprophylaxis. 25 Recommendations on dose selection have been formulated on the basis of individual bleeding risk as assessed by the introduced HAS-BLED stratification schema. The 150-mg bid dose is considered suitable for patients with low bleeding risk (score 0-2), while the 110-mg bid dose is reserved for high-risk patients (score 3). 25 In Canada, dabigatran gained approval for prevention of stroke and systemic embolism in patients with AF with the 110-mg bid dose recommended for elderly patients 80 years and patients at high risk of bleeding. 26 On the other hand, the Food and Drug Administration (FDA) only approved the 150-mg bid dabigatran dose, with a dosing recommendation of 75 mg bid in patients with severe renal insufficiency (creatinine clearance 15-30 mL/ min), triggering controversy regarding the decision to reject the lower dabigatran dose. Debate has been further fueled by a recent analysis of the RELY trial which demonstrated a significant age by treatment interaction for bleeding, with a significantly higher rate of major and extracranial bleeding among elderly patients (75 years) treated with dabigatran 150 mg bid compared with warfarin. 27 The FDA reported that the decision to approve only the 150-mg dose was partly determined by the trade-off between prevention of stroke and causation of hemorrhage. The committee expressed its concerns that the fear of bleeding would have an impact on the prescribing pattern with inappropriately high use of the lower dose and a resultant inferior efficacy in reducing stroke. 28 
Rivaroxaban
Rivaroxaban is an anticoagulant agent that targets the activated serine protease factor Xa, a key player in the blood coagulation cascade which catalyses the conversion of prothrombin into thrombin. 29 Rivaroxaban displays predictable pharmacokinetic and pharmacodynamic properties, with maximal plasma concentration achieved within 2 to 4 hours following intake. 29 It has no interaction with food and a low propensity for drug-drug interactions. 29 Despite its elimination half-life of 7 to 11 hours, the mediated inhibition of factor Xa activity is prolonged and therefore rivaroxaban can be administered in a once-daily dosing regimen without any need for regular coagulation monitoring. 28 In the extensive clinical program of the REgulation of Coagulation in ORthopedic surgery to prevent Deep vein thrombosis and pulmonary embolism (RECORD) trials, rivaroxaban showed superior efficacy and similar safety compared with enoxaparin in the prevention of venous thromboembolism in patients undergoing elective hip or knee replacement and has gained approval by the European Medicines Agency (EMA) for this indication. [30] [31] [32] [33] However, these results were not reproduced in the Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of VTE in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin (MAGELLAN) trial, where rivaroxaban was compared with enoxaparin for prevention of venous thromboembolism (VTE) among acutely ill medical patients. Indeed, extended treatment with rivaroxaban (10 mg once daily for 35 days) did not show a net clinical benefit across the entire study population, due to an increased bleeding rate and despite the reduction in the risk of VTE. 34 This discrepancy denotes that the bleeding rate and consequently the clinical benefit of anticoagulant agents is influenced by the characteristics of the patient population, since the patients enrolled in the MAGELLAN trial had more severe concurrent illnesses, associated comorbidities, and higher mortality rates. Rivaroxaban has been approved by the EMA and recently by the FDA for prevention of thromboembolic events after knee or hip replacement surgery. 35 Finally, the Anti-Xa Therapy to Lower cardiovascular events in addition to aspirin with/without thienopyridine therapy in subjects with Acute coronary Syndrome (ATLAS-ACS) trial, examining the combined use of rivaroxaban with antiplatelet therapy among patients with acute coronary syndrome has been recently completed and the results are going to be presented in the forthcoming American Heart Association (AHA) meeting. 36 In the treatment of acute deep vein thrombosis (DVT), rivaroxaban, as a single-drug approach, without the need for an initial overlap with heparin, was shown to be as effective as standard therapy, with similar safety properties, while the extension of anticoagulation treatment was shown to significantly reduce recurrences with an affordable risk of bleeding. 37 The performance of rivaroxaban in stroke prevention among patients with nonvalvular AF was tested in the Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonist for the prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial. In total, 14 264 patients were randomized to receive either a fixed dose of rivaroxaban 20-mg once daily (15 mg once daily for patients with creatinine clearance between 30 and 49 mL/min) or warfarin (target INR of 2.0-3.0) with a primary efficacy end point of stroke or systemic embolism. Rivaroxaban was noninferior to warfarin with a similar rate of major bleeding and a reduced rate of intracranial bleeding. Concerning superiority testing, rivaroxaban was superior to warfarin in the on-treatment analysis but without reaching statistical significance in the intention-to-treat (ITT) analysis. 38 
Apixaban
Apixaban is another factor Xa inhibitor. It has a bioavailability of 50% and is mainly eliminated via the intestinal route. In the Apixaban Dosed orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism (ADVANCE) clinical trial program, apixaban administered 2.5 mg bid was shown to be safe and effective in the prevention of VTE in patients who underwent elective orthopedic surgery with a prolonged postsurgery initiation window. [39] [40] [41] Apixaban was recently approved by the EMA for prevention of thromboembolic events after knee or hip surgery. 42 Apixaban has also been studied for stroke prevention in patients with AF who were considered unsuitable to receive VKA and was compared versus aspirin at a dose of 81 to 325 mg. 43 The study was prematurely terminated since apixaban was shown to significantly reduce the risk of stroke or systemic embolism compared with aspirin, with a similar risk of major bleeding. 43 The efficacy results of Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) were not a surprise taking into consideration that apixaban was compared against a ''weak'' opponent. Furthermore, as was the case in the ACTIVE-A trial, 16 the reasoning for patients' unsuitability for VKA therapy was not always robust since more than one third of patients were considered unsuitable due to their own refusal to take VKA. The conclusion of AVERROES is that whenever aspirin is the only option for stroke prevention in patients with AF, apixaban should be preferred. However, the impact of the trial results on everyday practice should not be overestimated especially in the context of the recently issued ESC guidelines which have downgraded the therapeutic role of aspirin in all thromboembolic risk categories. 25 The large phase III trial Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) was designed to compare apixaban 5 mg bid versus warfarin (INR 2.0-3.0) for stroke prevention in patients with AF. 44 Based on the preliminary results of the study, apixaban is noninferior to warfarin and also meets the key secondary end points of superiority on efficacy and on major bleeding compared with warfarin. 45 It should also be reported that the phase III trial Apixaban for Prevention of Acute Ischemic Events 2 (APPRAISE-2) enrolling high-risk patients with acute coronary syndromes who were randomized to receive either apixaban 5 mg bid or placebo on top of single or dual antiplatelet treatment was prematurely discontinued due to an associated increased bleeding risk. 46 
Edoxaban
Edoxaban is a direct Xa inhibitor with a half-life of 8 to 10 hours that is largely eliminated via the renal route. 47 A large phase III trial (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation, ENGAGE AF TIMI 48) comparing 2 different doses of edoxaban (60 and 30 mg once daily with the option of dose reduction in patients with anticipated increased drug exposure) versus warfarin for prevention of stroke and systemic embolism in patients with AF has completed recruitment and study completion is estimated 48, 49 in March 2012.
Selection of Novel Anticoagulants-Facts to Remember
As the list of novel anticoagulants is expected to get longer, physicians will face the dilemma what agent should they prescribe and why. The tendency to compare the treatment efficacy and safety of novel anticoagulants based on the existing trials is prone to bias. Indirect comparisons are misleading and only head-to-head randomized clinical trials could provide evidence-based clues. However, several issues regarding baseline characteristics of the phase III trials, study methodology, statistical analyses, and study results should be taken into account when making relevant commentaries.
Differences in Patient Populations
Patient populations in the RELY and ROCKET-AF differ markedly. The ROCKET-AF included an older (mean age 73 vs 71.5) and higher-risk population with significant comorbidities (increased prevalence of hypertension, congestive heart failure, prior stroke, or TIA) with a higher mean baseline Cardiac failure, Hypertension, Age, Diabetes, Stroke (doubled; [CHADS 2 ]) score (3.5 vs 2.1). These differences in baseline characteristics could at least partly explain the lower median TTR value achieved in the ROCKET-AF control group (58%) compared with the RELY trial (64%).
Pitfalls in Subgroup Analyses
The large sample size of these phase III mega trials offers the possibility of performing subgroup analyses mainly aiming to test the hypothesis whether the treatment effect is maintained in several subpopulations and to proceed with cross-trial comparisons. However, results derived from subgroup analyses should be interpreted with caution without exerting major influence on clinical decision making. These concerns stem from the following well-addressed shortcomings of subgroup analyses in randomized clinical trials: (a) post hoc subgroup analyses are commonly motivated by data inspection, (b) both prespecified and post hoc subgroup analyses are prone to falsepositive rates associated with multiplicity, (c) the power of subgroup analyses is usually inadequate to detect true differences in treatment effect, and (d) randomization of patient characteristics in the treatment and control groups is not necessarily maintained within the strata of each subgroup. Therefore, it would be prudent to use results from subgroup analyses mainly as hypothesis-generating data for further adequately powered specifically designed randomized trials.
Differences in Dosing Regimens
The once-daily dosing regimen of rivaroxaban and edoxaban offers a practical advantage in terms of convenience and patient compliance over the bid regimen of dabigatran and apixaban. This argument is further strengthened by the fact that treatment with anticoagulants is lifelong, in patients who usually feel well and therefore carry a high risk of missing doses and exposing themselves to the risk of breakthrough thrombosis.
Differences in Efficacy Results
In terms of efficacy, dabigatran 150 mg bid is superior to warfarin; dabigatran 110 mg bid has a similar efficacy compared with warfarin, and rivaroxaban is at least as effective as warfarin. However, in everyday practice, the relative treatment benefit gained by novel anticoagulants compared with warfarin is expected to be enhanced, since in the real world the quality of INR control is worse and the achieved TTR values are far less than those achieved in the setting of clinical trials.
Differences in Study Design
Differences in study design remain an issue of debate. The RELY trial has a prospective randomized open trial with blinded end point evaluation (PROBE) design with blinded patient randomization to different dabigatran doses, while AVERROES, ARISTOTLE, and the ROCKET-AF trial were conducted in a double-blind design. Although the doubleblind design is a priori considered the ideal study methodology due to elimination of bias, the PROBE design is considered to more accurately reflect what actually happens in everyday practice.
Intention-to-Treat Versus On-Treatment Analyses
In the ROCKET AF, rivaroxaban had superior efficacy compared with warfarin in the on-treatment but not in the ITT analysis. This discrepancy has triggered debate regarding the credibility of the on-treatment analysis in randomized clinical trials and the weight of evidence supporting superiority of rivaroxaban over warfarin. In theory, ITT is the ideal method of statistical analysis for all randomized clinical trials due to a negligible risk of introducing potential bias. On the other hand, the on-treatment analysis provides a more specific measure of the treatment effect and might be preferred for noninferiority studies, especially when a high rate of dropouts is expected. However, on-treatment analysis should not be used to justify superiority results and should be considered in the context of its methodological limitations.
Conclusions
The prevalence of AF is expected to rise due to aging of the general population and improved management of cardiovascular diseases. The increased epidemiological burden of AF combined with the broadening of the eligibility criteria for anticoagulation treatment among patients with AF will enhance the impact of underutilization of VKAs for thromboprophylaxis of patients with AF. From a pragmatic point of view, major benefit on a population basis will be gained not only by improving treatment efficacy compared with standard therapy among those already on VKAs but primarily by initiating anticoagulants in patients considered unsuitable or unwilling to take VKAs. Therefore, the enrichment of the therapeutic armamentarium with novel anticoagulants which are at least as effective as warfarin, with similar or even enhanced safety, and devoid of the limitations and troublesome practicalities of VKAs is a leap of progress.
